[{"id":"c8116811-cabb-4c96-b93a-f3d91f9efb1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04031872","created_at":"2021-06-09T12:59:41.544Z","updated_at":"2024-07-02T16:36:57.711Z","phase":"Phase 1/2","brief_title":"LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)","source_id_and_acronym":"NCT04031872","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • capecitabine • LY3200882"],"overall_status":"Unknown status","enrollment":" Enrollment 31","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2019-07-24"}]